WHO Mpox Clinical Data Platform
  • At a glance
  • Cases description
  • Skin lesions
  • Symptoms
  • HIV status
  • Exposures & diagnosis
  • Laboratory results
  • Treatments and outcomes

Data are provided by many contributors through the the WHO Clinical data platform and are not necessarily representative. To become a contributor, please see the terms of use and register here.

Total cases

26

Total facilities

2

Total PLWH

4

Women

30.8%

Children below 5

11.5%

Total deaths

0

The map below is just a proof of concept. Can be adjusted once/if we have data at the regional level.

Geospatial distribution
Cases reported
Mirror plots
Chronic conditions
Variable Sample size Prevalence pct Frequency
HIV (Human Immunodeficiency Virus) 26 15.4% 4 / 26
Hypertension 26 3.8% 1 / 26
Current new STI (Sexually Transmitted Infection) diagnosis? 26 3.8% 1 / 26
Syphilis 1 100.0% 1 / 1
Chronic heart disease 26 0.0% 0 / 26
Chronic lung disease 26 0.0% 0 / 26
Chronic kidney disease 26 0.0% 0 / 26
Chronic liver disease 26 0.0% 0 / 26
Chronic neurologic condition 26 0.0% 0 / 26
Current alcohol use disorder 26 0.0% 0 / 26
Previous COVID-19 infection 26 0.0% 0 / 26
Diabetes 26 0.0% 0 / 26
Currently smokes tobacco 26 0.0% 0 / 26
Skin Conditions 26 0.0% 0 / 26
Tuberculosis (previous) 26 0.0% 0 / 26
Tuberculosis (active) 26 0.0% 0 / 26
Asplenia 26 0.0% 0 / 26
Cancer 26 0.0% 0 / 26
Immunosuppressive condition 26 0.0% 0 / 26
N. gonorrhoeae 1 0.0% 0 / 1
HSV 1 0.0% 0 / 1
Chlamydia trachomatis 1 0.0% 0 / 1
HPV 1 0.0% 0 / 1
AIDS - defining illness 3 0.0% 0 / 3

Source: WHO

Complications
Variable Sample size Prevalence pct Frequency
Cellulitis 20 30.0% 6 / 20
Bacteraemia 20 20.0% 4 / 20
Bacterial Pneumonia 20 10.0% 2 / 20
Anaemia 20 5.0% 1 / 20
Sepsis 20 0.0% 0 / 20
Shock 20 0.0% 0 / 20
Seizure 20 0.0% 0 / 20
Encephalitis / Meningitis 20 0.0% 0 / 20
Bleeding Disorder 20 0.0% 0 / 20
Stroke / Cerebrovascular Accident 20 0.0% 0 / 20
Guillain-Barré Syndrome 20 0.0% 0 / 20
Cardiac Arrest 20 0.0% 0 / 20
Cardiac Arrhythmia 20 0.0% 0 / 20
Cardiomyopathy 20 0.0% 0 / 20
Myocarditis / Pericarditis 20 0.0% 0 / 20
Viral Pneumonia / Pneumonitis 20 0.0% 0 / 20
Acute Respiratory Distress Syndrome (Ards) 20 0.0% 0 / 20
Acute Renal Injury / Acute Renal Failure 20 0.0% 0 / 20
Pancreatitis 20 0.0% 0 / 20
Liver Dysfunction 20 0.0% 0 / 20
Urinary Retention 20 0.0% 0 / 20
Ocular Complications 20 0.0% 0 / 20
Necrotizing Infection 20 0.0% 0 / 20
Abscess 20 0.0% 0 / 20
Proctitis 20 0.0% 0 / 20
Rectal Urgency 20 0.0% 0 / 20
Rectal Pain 20 0.0% 0 / 20

Source: WHO

Body map of lesions at admission
Prevalence of lesions at admission
Variable Sample size Prevalence pct Frequency
Upper limb 25 100.0% 25/25
Head and neck 25 92.0% 23/25
Chest and abdomen 25 92.0% 23/25
Lower limb 25 92.0% 23/25
Back 25 80.0% 20/25
Genitals 25 48.0% 12/25
Mouth 25 44.0% 11/25

Source: WHO

Type of lesions
Variable Sample size Prevalence pct Frequency
Papule 26 92.3% 24/26
Umbilicated pustule 26 53.8% 14/26
Early vesicle 26 38.5% 10/26
Macule 26 34.6% 9/26
Small pustule 26 34.6% 9/26
Crusting of a mature lesion 26 30.8% 8/26
Ulcerated lesion 26 15.4% 4/26
Partially removed scab 26 15.4% 4/26

Source: WHO

Reported symptoms
Symptoms at admission
Variable Sample size Prevalence pct Frequency
Muscle pain or aching 26 76.9% 20 / 26
Fatigue or malaise 26 65.4% 17 / 26
Headache 26 57.7% 15 / 26
Sore throat 26 46.2% 12 / 26
Pain in mouth 26 46.2% 12 / 26
Swallowing problem 26 34.6% 9 / 26
Joint pain or aching 26 34.6% 9 / 26
Fever 9 88.9% 8 / 9
Painful swallow 9 88.9% 8 / 9
Pruritis/itching 9 77.8% 7 / 9
Psychologic disturbance 26 19.2% 5 / 26
Urinary symptoms 26 11.5% 3 / 26
Pain with urination 3 100.0% 3 / 3
Difficult swallow 9 33.3% 3 / 9
Ocular symptoms (pain, redness, visual loss) 26 0.0% 0 / 26
Nausea 26 0.0% 0 / 26
Vomiting 26 0.0% 0 / 26
Diarrhoea 26 0.0% 0 / 26
Any rectal symptom 26 0.0% 0 / 26
Chest pain 26 0.0% 0 / 26
Proctitis 26 0.0% 0 / 26
Dizziness 26 0.0% 0 / 26
Decrease urine output 3 0.0% 0 / 3
Urethral discharge 3 0.0% 0 / 3

Source: WHO

Symptoms at discharge
Variable Sample size Prevalence pct Frequency
Sore throat 20 5.0% 1 / 20
Muscle pain or aching 20 0.0% 0 / 20
Headache 20 0.0% 0 / 20
Ocular symptoms (pain, redness, visual loss) 20 0.0% 0 / 20
Fatigue or malaise 20 0.0% 0 / 20
Pain in mouth 20 0.0% 0 / 20
Nausea 20 0.0% 0 / 20
Vomiting 20 0.0% 0 / 20
Diarrhoea 20 0.0% 0 / 20
Any rectal symptom 20 0.0% 0 / 20
Swallowing problem 20 0.0% 0 / 20
Chest pain 20 0.0% 0 / 20
Joint pain or aching 20 0.0% 0 / 20
Proctitis 20 0.0% 0 / 20
Dizziness 20 0.0% 0 / 20
Psychologic disturbance 20 0.0% 0 / 20
Urinary symptoms 20 0.0% 0 / 20
Fever 9 0.0% 0 / 9
Pruritis/itching 9 0.0% 0 / 9

Source: WHO

  • HIV demographics
  • Some treatment metrics
  • Vaccination data
  • Immunosuppression status data
Variable

Person with HIV
N = 4

Person without HIV
N = 21

Unknown
N = 1

p-value 1
age, Median (Q1, Q3) 12.00 (6.00, 12.00) 8.00 (6.00, 10.00) 8.00 (8.00, 8.00) 0.5
    Missing/Unknown 1 0 0
Sex at birth, n (%)


0.086
    Male 3 (75%) 14 (67%) 0 (0%)
    Female 0 (0%) 7 (33%) 1 (100%)
    Intersex 0 (0%) 0 (0%) 0 (0%)
    Unknown 1 (25%) 0 (0%) 0 (0%)
Race, n (%)


0.4
    African/Black 3 (75%) 20 (95%) 1 (100%)
    Arab 0 (0%) 0 (0%) 0 (0%)
    Asian 0 (0%) 0 (0%) 0 (0%)
    Hispanic/Latino 0 (0%) 0 (0%) 0 (0%)
    Mixed Race 0 (0%) 0 (0%) 0 (0%)
    White 0 (0%) 0 (0%) 0 (0%)
    Unknown 1 (25%) 1 (4.8%) 0 (0%)
    Other 0 (0%) 0 (0%) 0 (0%)
health care worker, n (%)


0.2
    Yes 0 (0%) 0 (0%) 0 (0%)
    No 3 (75%) 21 (100%) 1 (100%)
    Unknown 1 (25%) 0 (0%) 0 (0%)
Laboratory worker, n (%)


0.2
    Yes 0 (0%) 0 (0%) 0 (0%)
    No 3 (75%) 21 (100%) 1 (100%)
    Unknown 1 (25%) 0 (0%) 0 (0%)
Sex worker, n (%)


0.042
    Yes 0 (0%) 0 (0%) 1 (100%)
    No 3 (75%) 19 (90%) 0 (0%)
    Unknown 1 (25%) 2 (9.5%) 0 (0%)
currently pregnant or was pregnant in the last 6 weeks?, n (%)


>0.9
    Yes 0 (NA%) 0 (0%) 0 (0%)
    No 0 (NA%) 7 (100%) 1 (100%)
    Unknown 0 (NA%) 0 (0%) 0 (0%)
    Missing/Unknown 4 14 0
Breastfeeding, n (%)



    Yes 0 (NA%) 0 (NA%) 0 (NA%)
    No 0 (NA%) 0 (NA%) 0 (NA%)
    Unknown 0 (NA%) 0 (NA%) 0 (NA%)
    Missing/Unknown 4 21 1
1

Kruskal-Wallis rank sum test; Fisher’s exact test

Variable

Person with HIV
N = 4

Person without HIV
N = 21

Unknown
N = 1

p-value 1
ever hospitalized, n (%)


0.5
    Yes 3 (100%) 12 (71%) 0 (NA%)
    No 0 (0%) 5 (29%) 0 (NA%)
    Unknown 0 (0%) 0 (0%) 0 (NA%)
    Missing/Unknown 1 4 1
Length of hospitalization, Median (Q1, Q3) 12 (12, 21) 9 (7, 12) NA (NA, NA) 0.079
    Missing/Unknown 1 9 1
Escalation of care, n (%)


0.2
    Yes 1 (33%) 0 (0%) 0 (NA%)
    No 2 (67%) 12 (100%) 0 (NA%)
    Unknown 0 (0%) 0 (0%) 0 (NA%)
    Missing/Unknown 1 9 1
supplemental oxygen, n (%)


0.2
    Yes 1 (33%) 0 (0%) 0 (NA%)
    No 2 (67%) 12 (100%) 0 (NA%)
    Unknown 0 (0%) 0 (0%) 0 (NA%)
    Missing/Unknown 1 9 1
receive nasogastric fluids, n (%)


>0.9
    Yes 0 (0%) 0 (0%) 0 (NA%)
    No 3 (100%) 17 (100%) 0 (NA%)
    Unknown 0 (0%) 0 (0%) 0 (NA%)
    Missing/Unknown 1 4 1
receive IV fluids during course monkeypox infection, n (%)


0.2
    Yes 1 (33%) 0 (0%) 0 (NA%)
    No 2 (67%) 17 (100%) 0 (NA%)
    Unknown 0 (0%) 0 (0%) 0 (NA%)
    Missing/Unknown 1 4 1
receive analgesia for pain management, n (%)


0.074
    Yes 3 (100%) 6 (35%) 0 (NA%)
    No 0 (0%) 11 (65%) 0 (NA%)
    Unknown 0 (0%) 0 (0%) 0 (NA%)
    Missing/Unknown 1 4 1
receive antibiotics during course monkeypox infection, n (%)


>0.9
    Yes 3 (100%) 16 (94%) 0 (NA%)
    No 0 (0%) 1 (5.9%) 0 (NA%)
    Unknown 0 (0%) 0 (0%) 0 (NA%)
    Missing/Unknown 1 4 1
receive antifungals during course monkeypox infection, n (%)


>0.9
    Yes 0 (0%) 0 (0%) 0 (NA%)
    No 3 (100%) 17 (100%) 0 (NA%)
    Unknown 0 (0%) 0 (0%) 0 (NA%)
    Missing/Unknown 1 4 1
experimental antiviral during course monkeypox infection, n (%)


>0.9
    Yes 0 (0%) 0 (0%) 0 (NA%)
    No 3 (100%) 17 (100%) 0 (NA%)
    Unknown 0 (0%) 0 (0%) 0 (NA%)
    Missing/Unknown 1 4 1
1

Fisher’s exact test; Kruskal-Wallis rank sum test

Variable

Person with HIV
N = 4

Person without HIV
N = 21

Unknown
N = 1

p-value 1
History of tetanus vaccination, n (%)


>0.9
    Yes 0 (0%) 0 (0%) 0 (0%)
    No 1 (25%) 8 (38%) 0 (0%)
    Unknown 3 (75%) 13 (62%) 1 (100%)
History of smallpox vaccination before 1980, n (%)


>0.9
    Yes 0 (0%) 0 (0%) 0 (0%)
    No 3 (75%) 17 (81%) 1 (100%)
    Unknown 1 (25%) 4 (19%) 0 (0%)
History of smallpox or monkeypox vaccination in past year, n (%)


0.5
    Yes 0 (0%) 0 (0%) 0 (0%)
    No 3 (75%) 19 (90%) 1 (100%)
    Unknown 1 (25%) 2 (9.5%) 0 (0%)
Number of vaccines received, Median (Q1, Q3) NA (NA, NA) NA (NA, NA) NA (NA, NA)
    Missing/Unknown 4 21 1
1

Fisher’s exact test

Variable

Person with HIV
N = 4

Person without HIV
N = 21

Unknown
N = 1

p-value 1
New diagnosis of HIV, n (%)


>0.9
    Yes 0 (0%) 0 (0%) 0 (NA%)
    No 2 (100%) 17 (100%) 0 (NA%)
    Unknown 0 (0%) 0 (0%) 0 (NA%)
    Missing/Unknown 2 4 1
Current new STI (Sexually Transmitted Infection) diagnosis, n (%)



    Yes 0 (0%) 0 (NA%) 0 (NA%)
    No 1 (100%) 0 (NA%) 0 (NA%)
    Unknown 0 (0%) 0 (NA%) 0 (NA%)
    Missing/Unknown 3 21 1
Immunosuppressive condition, n (%)


0.038
    Yes 0 (0%) 0 (0%) 0 (0%)
    No 4 (100%) 21 (100%) 0 (0%)
    Unknown 0 (0%) 0 (0%) 1 (100%)
Most recent CD4, Median (Q1, Q3) 98 (98, 98) NA (NA, NA) NA (NA, NA)
    Missing/Unknown 1 21 1
Viral load, n (%)



    Detectable 0 (0%) 0 (NA%) 0 (NA%)
    Undetectable 1 (33%) 0 (NA%) 0 (NA%)
    Unknown 2 (67%) 0 (NA%) 0 (NA%)
    Missing/Unknown 1 21 1
AIDS - defining illness, n (%)



    Yes 0 (0%) 0 (NA%) 0 (NA%)
    No 3 (100%) 0 (NA%) 0 (NA%)
    Unknown 0 (0%) 0 (NA%) 0 (NA%)
    Missing/Unknown 1 21 1
1

Fisher’s exact test

Skin lesions by HIV status
Complications by HIV status
Exposure distribution
Variable Sample size Prevalence pct Frequency
Sexually active within ≤ 21 days prior to symptom onset? 26 50.0% 13/26
Number of heterosexual partners in the last three months 13 92.3% 12/13
Any known link to probable or confirmed case of monkeypox within ≤ 21 days prior to symptom onset? 26 7.7% 2/26
International travel within ≤ 21 days prior to symptom onset? 26 3.8% 1/26
Contact with possible animal source within ≤ 21 days prior to symptom onset? 26 0.0% 0/26
Did the patient receive experimental antiviral during course monkeypox infection? 20 0.0% 0/20

Source: WHO

  • MPOX diagnosis
  • Orthopox diagnosis
  • Other diagnosis
Variable N = 26
Mpox clade known:, n (%)
    Yes 0 (0%)
    No 20 (100%)
    Unknown 0 (0%)
    Missing/Unknown 6
Mpox clade, n (%)
    Ia 0 (NA%)
    Ib 0 (NA%)
    IIa 0 (NA%)
    IIb 0 (NA%)
    Missing/Unknown 26
Monkeypox PCR, n (%)
    Yes 20 (100%)
    No 0 (0%)
    Unknown 0 (0%)
    Missing/Unknown 6
Monkeypox Result, n (%)
    Positive 6 (30%)
    Negative 13 (65%)
    Indeterminate 0 (0%)
    Unknown 1 (5.0%)
    Missing/Unknown 6
Monkeypox viral culture, n (%)
    Yes 0 (0%)
    No 20 (100%)
    Unknown 0 (0%)
    Missing/Unknown 6
Monkeypox viral culture Result, n (%)
    Positive 0 (NA%)
    Negative 0 (NA%)
    Indeterminate 0 (NA%)
    Unknown 0 (NA%)
    Missing/Unknown 26
Variable N = 26
Orthopoxvirus PCR, n (%)
    Yes 0 (0%)
    No 20 (100%)
    Unknown 0 (0%)
    Missing/Unknown 6
Orthopoxvirus Result, n (%)
    Positive 0 (NA%)
    Negative 0 (NA%)
    Indeterminate 0 (NA%)
    Unknown 0 (NA%)
    Missing/Unknown 26
Variable N = 26
Malaria result, n (%)
    Positive 0 (NA%)
    Negative 0 (NA%)
    Indeterminate 0 (NA%)
    Unknown 0 (NA%)
    Missing/Unknown 26
Syphilis result, n (%)
    Positive 0 (NA%)
    Negative 0 (NA%)
    Indeterminate 0 (NA%)
    Unknown 0 (NA%)
    Missing/Unknown 26
  • Baseline visit
  • During infection management
Variable

Baseline visit
N = 26

Hemoglobin, Median (Q1, Q3) 15.05 (12.05, 17.60)
WCC total, Median (Q1, Q3) 9.4 (5.1, 11.1)
Platelets, Median (Q1, Q3) 208 (144, 307)
PT, Median (Q1, Q3) NA (NA, NA)
APTT, Median (Q1, Q3) NA (NA, NA)
Total Bilirubin, Median (Q1, Q3) NA (NA, NA)
ALT, Median (Q1, Q3) NA (NA, NA)
AST, Median (Q1, Q3) NA (NA, NA)
Na+, Median (Q1, Q3) NA (NA, NA)
K+, Median (Q1, Q3) NA (NA, NA)
Urea/BUN, Median (Q1, Q3) NA (NA, NA)
Creatinine, Median (Q1, Q3) NA (NA, NA)
Glucose, Median (Q1, Q3) NA (NA, NA)
Lactate, Median (Q1, Q3) NA (NA, NA)
CRP, Median (Q1, Q3) NA (NA, NA)
Creatine kinase, Median (Q1, Q3) NA (NA, NA)
Variable

During infection management
N = 48

Hemoglobin, Median (Q1, Q3) 15.05 (12.05, 17.60)
WCC total, Median (Q1, Q3) 9.4 (5.1, 11.1)
Platelets, Median (Q1, Q3) 208 (144, 307)
PT, Median (Q1, Q3) NA (NA, NA)
APTT, Median (Q1, Q3) NA (NA, NA)
Total Bilirubin, Median (Q1, Q3) NA (NA, NA)
ALT, Median (Q1, Q3) NA (NA, NA)
AST, Median (Q1, Q3) NA (NA, NA)
Na+, Median (Q1, Q3) NA (NA, NA)
K+, Median (Q1, Q3) NA (NA, NA)
Urea/BUN, Median (Q1, Q3) NA (NA, NA)
Creatinine, Median (Q1, Q3) NA (NA, NA)
Glucose, Median (Q1, Q3) NA (NA, NA)
Lactate, Median (Q1, Q3) NA (NA, NA)
CRP, Median (Q1, Q3) NA (NA, NA)
Creatine kinase, Median (Q1, Q3) NA (NA, NA)
  • Baseline advanced
Variables Lab measures distribution
N Mean Median Min Max Distribution
Baseline visit
Hemoglobin 8.00 14.21 15.05 6.30 18.00
Platelets 8.00 267.50 207.50 93.00 731.00
WCC total 8.00 10.38 9.35 3.00 29.00
  • Antibiotics
Outcomes


This dashboard displays statistics for:

Total cases: 26
Total reporting countries 1
As of: 2024-10-16




Disclaimer

Data are provided by many contributors through the the WHO Clinical data platform and are not necessarily representative. To become a contributor, please see the terms of use and register here.